Vendor Intelligence Report: Changsha Xjun Technology

Published 3 Jul 2026. 26-page investigative report on who is behind Changsha Xjun Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, Changsha Xjun Technology is 5 pass / 1 fail, for an overall pass rate of 83%. That signal is narrow: every Finnrick result in the dossier is Retatrutide. For a buyer comparing Chinese B2B sources specifically for Retatrutide, Xjun is more knowable than a no-data storefront; for the rest of its expanded catalog, the Finnrick record does not transfer.

The buyer-useful read is mixed rather than binary. Retatrutide is the comparatively better-supported choice, but field records flag weak batch identifiers, score dispersion, and ratings that fall under stricter grading. The eChem storefront has grown sharply, while chjunxi.com appears to serve email infrastructure rather than an independent public site with official-channel controls, COA verification, or anti-counterfeit tools.

The non-lab investigation adds two material context pieces. Xjun’s eChem history includes 1,4-butanediol trading, including an Australia Stock claim during a period of Australian BDO enforcement and EU trade action; that is a logistics and compliance risk even for peptide buyers. Corporate registry work hit Chinese login/CAPTCHA barriers, sales run through multiple personas and mixed phone geographies, and the Caoquan Technology lead remains a same-ecosystem signal rather than a proven sister brand.

The public footprint is thin but not dominated by obvious promotion. PeptideTally shows a new mid-range profile with no visitor reviews, while the open-web coupon and influencer sweep found no Xjun-specific discount-code machine. The practical read is to treat Xjun as a Retatrutide-only, lot-verification case, not a broadly validated peptide catalog.

Inside the full report:

  • Complete Retatrutide pass/fail history and methodology-divergence charts in Appendix A — Finnrick Laboratory Data
  • eChem storefront captures showing tenure-indicator changes, catalog expansion, sales personas, and BDO listings
  • chjunxi.com WHOIS and Wayback exhibits covering Alibaba/HiChina DNS and the absence of archived public site content
  • Corporate-registry verification attempts across Tianyancha, Qichacha, and national registry paths
  • BDO regulatory-risk analysis covering Australia-stock language, Australian enforcement context, and EU trade action
  • Caoquan Technology network-lead assessment plus affiliate, coupon, and open-web promotion sweep results

Risk assessment

  • BDO regulatory-exposure risk — high: Xjun lists 1,4-butanediol and field materials tied the vendor to an “Australia Stock” BDO claim amid active Australian enforcement and EU duties on Chinese BDO.
  • Retatrutide quality-control and traceability risk — high: Retatrutide is the only Finnrick-tested product, with 6 tests, 5 pass / 1 fail, and an 80.35% rating, but field records still flag batch inconsistency and weak lot identification.
  • Non-Retatrutide product verification risk — medium: No Finnrick pass/fail history is supplied for the rest of the approximately 93-product catalog, including Semaglutide, Tirzepatide, Cagrilintide, Liraglutide, GHK-Cu, NAD+, and TB-500.
  • Corporate and official-channel opacity — medium: Chinese registry ownership was not verified; chjunxi.com has no public site/Wayback content and sales run through eChem personas rather than an auditable official-channel system.
  • Unverified third-party testing claim risk — medium: The TB-500 listing claimed Janoshik testing, but investigators did not locate a matching public certificate; buyers need lab-verifiable COAs.